Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy
Authors:
- 23 February 2016
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 63 (6) , 1113-1115
Abstract
Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Conversions of leukemia cell lineage are rare, but occur most commonly in the setting of MLL‐rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 with significant activity in relapsed B‐precursor ALL. We report an infant with ALL with t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated with blinatumomab. Following rapid initial clearance of peripheral lymphoblasts, bone marrow evaluation demonstrated a leukemic lineage switch to CD19‐negative monoblastic AML. Complete remission was achieved with myeloid‐directed chemotherapy.Keywords
This publication has 18 references indexed in Scilit:
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood, 2012
- Lineage switch in childhood acute leukemia: An unusual event with poor outcomeAmerican Journal of Hematology, 2012
- Insights into the cellular origin and etiology of the infant pro-B acute lymphoblastic leukemia with MLL-AF4 rearrangementLeukemia, 2010
- Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemiaLeukemia, 2010
- Infant acute lymphoblastic leukemia with t(11;16)(q23;p13.3) and lineage switch into acute monoblastic leukemiaCancer Genetics and Cytogenetics, 2006
- CongenitalMLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangementLeukemia & Lymphoma, 2005
- Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody constructInternational Journal of Cancer, 2005
- A lineage switch from AML to ALL with persistent translocation t(4;11) in congenital leukemiaMedical and Pediatric Oncology, 2003
- Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibodyInternational Journal of Cancer, 2002
- Phenotypic conversion of acute leukaemia from T‐lymphoblastic to myeloblastic induced by therapy with 2′‐deoxycoformycinBritish Journal of Haematology, 1983